Fatty acid oxidation inhibitors

Fatty acid oxidation inhibitors are a new potent class of drugs used in treatment of stable angina pectoris and an addition in treatment of chronic heart failure.

Drugs

• CPT-I inhibitors: Etomoxir, Oxfenicine, Perhexiline
  CPT-I (carnitine palmitoyl transferase) converts fatty acyl-CoA to fatty acyl-carnitine.
• Carnitine biosynthesis inhibitor: Mildronate^[1]
• 3-KAT inhibitors: Trimetazidine
  3-KAT (3-ketoacyl-coenzyme A thiolase) inhibitors directly inhibits fatty acid beta-oxidation.
• pFOX (partial fatty acid oxidation inhibitors): Ranolazine
  pFOX directly inhibits fatty acid beta-oxidation.^[2]

References

1. J Cardiovasc Pharmacol. 2006 Dec;48(6):314-9.; Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. ; Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M.;Latvian Institute of Organic Synthesis, Riga, Latvia.http://www.ncbi.nlm.nih.gov/pubmed/17204911
2. Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure; European Journal of Heart Failure 4 2002. 3-6; http://eurjhf.oxfordjournals.org/content/4/1/3.full.pdf+html